1. Discovery of IRAK4 Inhibitors BAY1834845(Zabedosertib) and BAY1830839
- Author
-
Bothe, Ulrich, Günther, Judith, Nubbemeyer, Reinhard, Siebeneicher, Holger, Ring, Sven, Bömer, Ulf, Peters, Michaele, Rausch, Alexandra, Denner, Karsten, Himmel, Herbert, Sutter, Andreas, Terebesi, Ildiko, Lange, Martin, Wengner, Antje M., Guimond, Nicolas, Thaler, Tobias, Platzek, Johannes, Eberspächer, Uwe, Schäfer, Martina, Steuber, Holger, Zollner, Thomas M., Steinmeyer, Andreas, and Schmidt, Nicole
- Abstract
Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a critical role in innate inflammatory processes. Here, we describe the discovery of two clinical candidate IRAK4 inhibitors, BAY1834845(zabedosertib) and BAY1830839, starting from a high-throughput screening hit derived from Bayer’s compound library. By exploiting binding site features distinct to IRAK4 using an in-house docking model, liabilities of the original hit could surprisingly be overcome to confer both candidates with a unique combination of good potency and selectivity. Favorable DMPK profiles and activity in animal inflammation models led to the selection of these two compounds for clinical development in patients.
- Published
- 2024
- Full Text
- View/download PDF